Baby Formula Recall

Glaxo forecasts cut as Avandia reaches end of road Reuters By Ben Hirschler LONDON, Sept 24 (Reuters) - Analysts cut earnings forecasts for GlaxoSmithKline (GSK.L) on Friday after regulators moved to end most use of Avandia, although the impact was limited as sales of the diabetes drug were already set to tail ... See all stories on this topic »

Baby Formula Recall WPEC That recall involving baby formula has parents around the country worried. But doctors are urging people to stay calm. The maker of the top selling baby formula, Similac say chances are slim that kids consumed tainted formula. ... See all stories on this topic »

Mammograms less effective in detecting cancer Times of India A research, published in New England Journal of Medicine , is the latest to show that the benefits of mammography are limited and will open up debate over the treatment. The World Health Organisation (WHO) estimates that mammograms reduce the breast ... See all stories on this topic »

DEA: Surrender Your Unused Prescription Drugs Saturday RedOrbit The US Drug Enforcement Administration is holding its first ever "National Take-Back Day" this Saturday, asking members of the public to turn in their unused, expired or unwanted prescription medications at one of more than 4000 nationwide collection ... See all stories on this topic »

More Americans Becoming Obese: Report RedOrbit The United States is at the forefront of the world's richest countries that are getting fatter and fatter, according to an organization of leading economies on Thursday. The first ever forecast on obesity says three out of four Americans will be ... See all stories on this topic »

Want to Lose Weight? Find a Heavy Roommate TIME By Alice Park Thursday, September 23, 2010 | 0 comments The myth of the dreaded "freshman 15," it seems, is greatly exaggerated. That's the average amount of weight that college freshmen supposedly gain after moving into dorms where beer and pizza are ... See all stories on this topic »

AstraZeneca,BMS Report New Study On Diabetes Pill Dapagliflozin Wall Street Journal LONDON (Dow Jones)--AstraZeneca PLC (AZN) and partner Bristol-Myers Squibb Co. (BMY) Friday said a late-stage study found their new dapagliflozin pill for treating Type 2 diabetes had similar results in patients with low blood sugar when given along ... See all stories on this topic »